The 5 most recent market catalysts affecting $OBIO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 65
Orchestra BioMed Announces Receipt Of $6.1M Milestone Payment From Haemonetics' Acquisition Of Vivasure Medica
This headline represents a positive corporate catalyst for Orchestra BioMed (OBIO) as it receives a significant non-dilutive cash injection, strengthening its balance sheet and pot…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 75
Orchestra BioMed shares are trading higher after BTIG upgraded the stock from Neutral to Buy rating and announced a $10 price target.
This headline represents a significant corporate catalyst for Orchestra BioMed. An analyst upgrade from 'Neutral' to 'Buy' by a reputable firm like BTIG, coupled with a substantial…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Upgrades Orchestra BioMed Hldgs to Buy, Announces $10 Price Target
BTIG analyst Marie Thibault upgraded Orchestra BioMed Holdings (OBIO) from Neutral to Buy and announced a $10 price target. This upgrade reflects a more optimistic outlook from a r…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 60
Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10
Piper Sandler analyst Matt O'Brien has reaffirmed an 'Overweight' rating for Orchestra BioMed Holdings (OBIO) and raised the price target from $9 to $10. This move indicates that t…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 95
Orchestra BioMed Hldgs Q2 EPS $(0.38) Misses $(0.37) Estimate, Sales $88.000K Miss $121.400K Estimate
Orchestra BioMed Holdings (OBIO) reported Q2 earnings per share of $(0.38), missing the analyst consensus of $(0.37), and sales of $88,000, significantly missing the $121,400 estim…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.